JP2021512637A5 - - Google Patents
Info
- Publication number
- JP2021512637A5 JP2021512637A5 JP2020543065A JP2020543065A JP2021512637A5 JP 2021512637 A5 JP2021512637 A5 JP 2021512637A5 JP 2020543065 A JP2020543065 A JP 2020543065A JP 2020543065 A JP2020543065 A JP 2020543065A JP 2021512637 A5 JP2021512637 A5 JP 2021512637A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain
- domain
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023126157A JP2023133505A (ja) | 2018-02-12 | 2023-08-02 | サイクリンａ１特異的ｔ細胞受容体およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629648P | 2018-02-12 | 2018-02-12 | |
| US62/629,648 | 2018-02-12 | ||
| US201862630198P | 2018-02-13 | 2018-02-13 | |
| US62/630,198 | 2018-02-13 | ||
| US201862667207P | 2018-05-04 | 2018-05-04 | |
| US62/667,207 | 2018-05-04 | ||
| PCT/US2019/017708 WO2019157524A1 (en) | 2018-02-12 | 2019-02-12 | Cyclin a1 specific t cell receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126157A Division JP2023133505A (ja) | 2018-02-12 | 2023-08-02 | サイクリンａ１特異的ｔ細胞受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512637A JP2021512637A (ja) | 2021-05-20 |
| JP2021512637A5 true JP2021512637A5 (https=) | 2022-02-22 |
| JPWO2019157524A5 JPWO2019157524A5 (https=) | 2022-02-22 |
Family
ID=65767286
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543065A Pending JP2021512637A (ja) | 2018-02-12 | 2019-02-12 | サイクリンａ１特異的ｔ細胞受容体およびその使用 |
| JP2023126157A Pending JP2023133505A (ja) | 2018-02-12 | 2023-08-02 | サイクリンａ１特異的ｔ細胞受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126157A Pending JP2023133505A (ja) | 2018-02-12 | 2023-08-02 | サイクリンａ１特異的ｔ細胞受容体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12570712B2 (https=) |
| EP (1) | EP3752525A1 (https=) |
| JP (2) | JP2021512637A (https=) |
| CN (1) | CN112004825A (https=) |
| AU (1) | AU2019218397A1 (https=) |
| BR (1) | BR112020016330A8 (https=) |
| CA (1) | CA3090700A1 (https=) |
| IL (1) | IL276556A (https=) |
| MX (1) | MX2020008403A (https=) |
| SG (1) | SG11202007660UA (https=) |
| WO (1) | WO2019157524A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220095228A (ko) * | 2019-11-06 | 2022-07-06 | 베이롤 칼리지 오브 메드신 | 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법 |
| CN113321725B (zh) * | 2020-02-28 | 2024-06-11 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的t细胞受体 |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| CN113880953A (zh) * | 2020-07-01 | 2022-01-04 | 华夏英泰（北京）生物技术有限公司 | T细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| WO2022022696A1 (zh) * | 2020-07-30 | 2022-02-03 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的高亲和力tcr |
| KR20230133878A (ko) * | 2021-01-19 | 2023-09-19 | 우시 바이올로직스 아일랜드 리미티드 | 안정성 및 발현이 향상된 폴리펩티드 복합체 |
| MX2023012141A (es) * | 2021-04-14 | 2023-11-28 | Tscan Therapeutics Inc | Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos. |
| EP4731758A2 (en) * | 2023-06-20 | 2026-04-29 | The Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US20020053092A1 (en) | 1997-11-14 | 2002-05-02 | Readhead Carol W. | Nucleic acid constructs containing a cyclin A1 promoter, and kit |
| US6461813B2 (en) | 1998-09-21 | 2002-10-08 | Rigel Pharmaceuticals, Inc. | Multiparameter FACS assays to detect alterations in cell cycle regulation |
| CN1560078B (zh) | 1998-07-31 | 2011-06-22 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2004024175A1 (ja) | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| ES2556232T3 (es) | 2004-03-31 | 2016-01-14 | International Institute Of Cancer Immunology, Inc. | Péptidos antigénicos del cáncer derivados de WT1 |
| JP2008527001A (ja) | 2005-01-13 | 2008-07-24 | ザ ジョンズ ホプキンス ユニバーシティー | 前立腺幹細胞抗原ワクチンおよびその使用 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| EP2203746B1 (en) | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| JP6120848B2 (ja) | 2011-08-15 | 2017-04-26 | メディミューン，エルエルシー | 抗ｂ７−ｈ４抗体およびその使用 |
| KR102134932B1 (ko) | 2011-11-11 | 2020-07-17 | 프레드 헛친슨 켄서 리서치 센터 | 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법 |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| US10317402B2 (en) | 2014-12-03 | 2019-06-11 | Verik Bio, Inc. | Identification, selection and use of high curative potential T cell epitopes |
| AU2016242967B2 (en) | 2015-04-01 | 2021-07-01 | Adaptive Biotechnologies Corp. | Method of identifying human compatible T cell receptors specific for an antigenic target |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| GB201604494D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
-
2019
- 2019-02-12 CN CN201980025483.1A patent/CN112004825A/zh active Pending
- 2019-02-12 JP JP2020543065A patent/JP2021512637A/ja active Pending
- 2019-02-12 US US16/968,547 patent/US12570712B2/en active Active
- 2019-02-12 SG SG11202007660UA patent/SG11202007660UA/en unknown
- 2019-02-12 MX MX2020008403A patent/MX2020008403A/es unknown
- 2019-02-12 CA CA3090700A patent/CA3090700A1/en active Pending
- 2019-02-12 EP EP19711182.6A patent/EP3752525A1/en active Pending
- 2019-02-12 AU AU2019218397A patent/AU2019218397A1/en not_active Abandoned
- 2019-02-12 WO PCT/US2019/017708 patent/WO2019157524A1/en not_active Ceased
- 2019-02-12 BR BR112020016330A patent/BR112020016330A8/pt not_active IP Right Cessation
-
2020
- 2020-08-06 IL IL276556A patent/IL276556A/en unknown
-
2023
- 2023-08-02 JP JP2023126157A patent/JP2023133505A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512637A5 (https=) | ||
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| AU2022231657B2 (en) | Compositions and Methods for Treating Cancer | |
| Schooten et al. | MAGE-A antigens as targets for cancer immunotherapy | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| JP6974311B2 (ja) | 新規ｐｄ−１免疫調節剤 | |
| JP2022116230A (ja) | 免疫療法用改変細胞 | |
| US12577311B2 (en) | Chimeric antigen receptor factories and methods of use thereof | |
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| JP2017531687A5 (https=) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| JP2020533962A5 (https=) | ||
| Yang et al. | Opportunities and challenges for antibodies against intracellular antigens | |
| JPWO2019157524A5 (https=) | ||
| EP3710472A1 (en) | Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof | |
| JP2024541175A (ja) | Ｈｅｒｖ－ｋ抗体治療法 | |
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| TWI805792B (zh) | 抗腫瘤劑及其評估方法 | |
| Sallman et al. | Is disease-specific immunotherapy a potential reality for MDS? | |
| US20240148867A1 (en) | Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine | |
| Subklewe | Current status of immunotherapy in acute myeloid leukemia | |
| Baybutt | CD8ɑ Structural Domains Enhance GUCY2C CAR-T Cell Efficacy | |
| HK40097672A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| HK40097671A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| HK40109798A (zh) | 制导和导航控制蛋白及其制备和使用方法 |